Novo Nordisk Falls Most on Record After New Weight Drug Disappoints – Bloomberg By Weight Loss Novo Nordisk Falls Most on Record After New Weight Drug Disappoints Bloomberg Novo Nordisk shares tumble as weight-loss drug trial data disappoints Financial Times Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it CNN Brought to you by Google News. Read the rest of the article here Facebook Twitter Pinterest